Patents by Inventor Daniel Olive

Daniel Olive has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL ANTI-NECTIN-4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20260062481
    Abstract: The present invention relates to novel anti Nectin-4 antibodies and antibody-drug conjugates comprising these antibodies, as well as to the use thereof.
    Type: Application
    Filed: July 20, 2023
    Publication date: March 5, 2026
    Inventors: Jack ELANDS, Florence LHOSPICE, Marc LOPEZ, Daniel OLIVE, Xavier PREVILLE
  • ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOAD
    Publication number: 20260021194
    Abstract: The present disclosure provides Nectin-4 antibody drug conjugates (ADCs) comprising exatecan and pharmaceutical compositions thereof, and methods of using the ADCs for the treatment of cancer.
    Type: Application
    Filed: July 31, 2025
    Publication date: January 22, 2026
    Inventors: Jacobus Petrus Maria ELANDS, Joanna FARES, Guy FOURNET, Benoit JOSEPH, Florence LHOSPICE, Marc LOPEZ, Daniel OLIVE, Xavier PREVILLE, Warren VIRICEL
  • Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload
    Patent number: 12419964
    Abstract: The present disclosure provides Nectin-4 antibody drug conjugates (ADCs) comprising exatecan and pharmaceutical compositions thereof, and methods of using the ADCs for the treatment of cancer.
    Type: Grant
    Filed: October 2, 2024
    Date of Patent: September 23, 2025
    Assignees: ELI LILLY AND COMPANY, UNIVERSITÉ D'AIX-MARSEILLE, INSERM (Institut National De La Sante Et De La Recherche Medicale), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, MABLINK BIOSCIENCE, UNIVERSITE CLAUDE BERNARD LYON
    Inventors: Jacobus Petrus Maria Elands, Joanna Fares, Guy Fournet, Benoit Joseph, Florence Lhospice, Marc Lopez, Daniel Olive, Xavier Preville, Warren Viricel
  • Antibodies having specificity for nectin-4 and uses thereof
    Patent number: 12398206
    Abstract: The present invention relates to antibodies having specificity for Nectin-4 and uses thereof, in particular for the treatment of cancer.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: August 26, 2025
    Assignees: UNIVERSITÉ D'AIXMARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Marc Lopez, Daniel Olive
  • Novel formats of anti-CD28/sPD-1 fusion constructs
    Publication number: 20250197499
    Abstract: The invention relates to a bispecific protein complex of a defined structure, said complex being able to bind to CD28 as well as to PD-L1 and/or PD-L2. It also relates to the use of said bispecific protein complex as a medicament, or for treating a cancer.
    Type: Application
    Filed: March 21, 2023
    Publication date: June 19, 2025
    Inventors: Daniel OLIVE, Greg ELSON
  • BUTYROPHILIN (BTN) 3A ACTIVATING ANTIBODIES FOR USE IN METHODS FOR TREATING INFECTIOUS DISORDERS
    Publication number: 20250129165
    Abstract: The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.
    Type: Application
    Filed: October 27, 2022
    Publication date: April 24, 2025
    Applicants: IMCHECK THERAPEUTICS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ D'AIX-MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT JEAN PAOLI & IRENE CALMETTES, ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE, INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT
    Inventors: Daniel OLIVE, Soraya MEZOUAR, Jean-Louis MEGE, Paul FROHNA, Alemseged TRUNEH, Laetitia GAY
  • ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOAD
    Publication number: 20250127916
    Abstract: The present disclosure provides Nectin-4 antibody drug conjugates (ADCs) comprising exatecan and pharmaceutical compositions thereof, and methods of using the ADCs for the treatment of cancer.
    Type: Application
    Filed: October 2, 2024
    Publication date: April 24, 2025
    Inventors: Jacobus Petrus Maria ELANDS, Joanna FARES, Guy FOURNET, Benoit JOSEPH, Florence LHOSPICE, Marc LOPEZ, Daniel OLIVE, Xavier PREVILLE, Warren VIRICEL
  • Antibodies having specificity for BTN2 and uses thereof
    Patent number: 12258400
    Abstract: The present invention relates to antibodies having specificity for BTN2A and uses thereof, in particular for the treatment of cancer.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: March 25, 2025
    Assignees: IMCHECK THERAPEUTICS SAS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS—, INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITÉ D'AIX-MARSEILLE
    Inventors: Etienne Foucher, Carla Cano, Kieu Suong Le, Christine Pasero, Daniel Olive
  • BTN3A binding proteins and uses thereof
    Patent number: 12247075
    Abstract: It is disclosed anti-BTN3A activating antibody fragments that specifically bind to BTN3A and activate the cytolytic function of V?9/V?2 T cells. The disclosure more specifically relates to specific anti-BTN3A binding proteins comprising such activating antibody fragments and their use in the manufacturing of novel drugs for use in treating cancer disorders, in particular cancers susceptible to be treated with activated ?? T cells.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: March 11, 2025
    Assignees: IMCHECK THERAPEUTICS SAS, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX-MARSEILLE
    Inventors: Alemseged Truneh, Christine Pasero, René Hoet, Magali Colazet, Daniel Olive
  • ANTI-NECTIN-4-ANTIBODIES AND USES THEREOF
    Publication number: 20250018053
    Abstract: The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.
    Type: Application
    Filed: June 17, 2024
    Publication date: January 16, 2025
    Inventors: Jack ELANDS, Florence L'HOSPICE, Marc LOPEZ, Daniel OLIVE, Xavier PRÉVILLE
  • Anti-nectin-4-antibodies and uses thereof
    Patent number: 12049500
    Abstract: The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.
    Type: Grant
    Filed: March 31, 2022
    Date of Patent: July 30, 2024
    Assignees: EMERGENCE THERAPEUTICS GmbH, UNIVERSITE D'AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS-
    Inventors: Jack Elands, Florence L'Hospice, Xavier Préville, Daniel Olive, Marc Lopez
  • ANTI-NECTIN-4 ANTIBODY AMANITIN CONJUGATES
    Publication number: 20240181075
    Abstract: The present invention relates to an antibody-drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4 and wherein the drug is an amatoxin, particularly ?-amanitin.
    Type: Application
    Filed: March 31, 2022
    Publication date: June 6, 2024
    Applicants: EMERGENCE THERAPEUTICS AG, UNIVERSITE D’AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRS
    Inventors: Jack ELANDS, Florence LHOSPPICE, Xavier PRÉVILLE, Daniel OLIVE, Marc LOPEZ
  • ANTI-NECTIN-4-ANTIBODY EXATECAN CONJUGATES
    Publication number: 20240173424
    Abstract: The present invention relates to an antibody -drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4 and wherein the drug is a topoisomerase I inhibitor, particularly exatecan.
    Type: Application
    Filed: March 31, 2022
    Publication date: May 30, 2024
    Applicants: EMERGENCE THERAPEUTICS AG, UNIVERSITE D’AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRS
    Inventors: Jack ELANDS, Florence LHOSPPICE, Xavier PRÉVILLE, Daniel OLIVE, Marc LOPEZ
  • Anti-BTN3A antibodies and their use in treating cancer or infectious disorders
    Patent number: 11987631
    Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: May 21, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Alemseged Truneh, Daniel Olive, Christine Pasero, Aude De Gassart
  • ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF
    Publication number: 20240117041
    Abstract: The present invention relates to antibodies having specificity for BTN2 and uses thereof, in particular for the treatment of cancer.
    Type: Application
    Filed: December 28, 2022
    Publication date: April 11, 2024
    Inventors: Daniel OLIVE, Christine PASERO
  • Anti-BTN3A antibodies and their use in treating cancer or infectious disorders
    Patent number: 11945871
    Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.
    Type: Grant
    Filed: June 1, 2023
    Date of Patent: April 2, 2024
    Assignees: IMCHECK THERAPEUTICS SAS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Alemseged Truneh, Daniel Olive, Christine Pasero, Aude De Gassart
  • Anti-CD277 antibodies
    Patent number: 11904004
    Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: February 20, 2024
    Assignees: INSERM, UNIVERSITE D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CNRS, UNIVERSITE DE NANTES
    Inventors: Daniel Olive, Marc Bonneville, Emmanuel Scotet, Christelle Harly, Yves Guillaume
  • ANTI-NECTIN-4-ANTIBODIES AND USES THEREOF
    Publication number: 20240034791
    Abstract: The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.
    Type: Application
    Filed: March 31, 2022
    Publication date: February 1, 2024
    Applicants: EMERGENCE THERAPEUTICS AG, UNIVERSITE D’AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRS –
    Inventors: Jack ELANDS, Florence LHOSPPICE, Xavier PRÉVILLE, Daniel OLIVE, Marc LOPEZ
  • ANTI-CD25 ANTIBODIES
    Publication number: 20240002522
    Abstract: Novel anti-human CD25 antibodies or antigen-binding fragments thereof and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or antigen-binding fragment thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: January 4, 2024
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, INSTITUT JEAN PAOLI & IRENE CALMETTES, ALDERANN BIOTECHNOLOGY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AIX MARSEILLE, UNIVERSITE PARIS CITE, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
    Inventors: Daniel OLIVE, Armand BENSUSSAN, Jerome GIUSTINIANI, Anne MARIE-CARDINE, Amaud FOUSSAT, Jemila HOUACINE
  • ANTI-CD25 ANTIBODIES
    Publication number: 20240002521
    Abstract: Novel anti-human CD25 antibodies and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or an antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: January 4, 2024
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, ALDERAAN BIOTECHNOLOGY, UNIVERSITE D'AIX MARSEILLE, UNIVERSITÉ PARIS CITÉ, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
    Inventors: Daniel OLIVE, Armand BENSUSSAN, Jérôme GIUSTINIANI, Anne MARIE-CARDINE, Amaud FOUSSAT, Jemila HOUACINE